Clinical trial · Observational
Investigating the Efficacy of Hair Sparing Radiotherapy Treatment to the Whole Brain.
Investigating the Efficacy of Scalp Sparing Radiotherapy Treatment to the Whole Brain: Examining the Effect of Hair Loss and Re-growth
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Poor recruitment and follow up
Summary
Brief summary (as posted)
To investigate the use of a scalp sparing technique of radiotherapy treatment designed to treat the whole brain. Current treatment methods to treat the whole brain with radiotherapy result in complete alopecia as a side effect. Hair loss is usually patchy and uneven and re-growth similar and slow. It is hoped that reducing the radiation dose to the hair bearing follicle on the scalp will reduce hair loss and increase the speed and evenness of re-growth.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Brain Cancer | Malignant Brain Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| VMAT (Volumetric Modulated Arc Therapy) | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- VMAT WBRT
- description
- Patients requiring whole brain radiotherapy as part of their cancer managment.
- interventionNames
- Radiation: VMAT (Volumetric Modulated Arc Therapy)
Primary outcomes (1)
- measure
- To assess hair loss and hair regrowth in patients undergoing WBRT using VMAT via photographic assessment by independent professionals at intervals up to 16 weeks post end of treatment.
- timeFrame
- 4 months post radiotherapy treatment
Secondary outcomes (1)
- measure
- To assess patient perceptions of hair loss and hair regrowth in patients undergoing WBRT using VMAT via self assessment at intervals up to 16 weeks post end of treatment.
- timeFrame
- 4 months post radiotherapy treatment end
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adults over 18 * Positive cancer diagnosis * Either proven brain metastasis or prophylaxis for primary lung cancer * Have no epilating chemotherapy planned * Basic understanding of English Exclusion Criteria: * Previous whole brain radiotherapy * Pregnant females * Unable to give informed consent * Urgent cases that need same or next day treatment when referred
References
Publications (0)
Data not yet available